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Abstract
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutane-
ous coronary intervention (PCI). Following balloon injury and stent placement, the intima at
the site is distressed, resulting in the activation of coagulation cascade and platelets. In the
case of bare metal stents (BMS), it takes six to eight weeks for the stent surface to be covered
with neointima. However, in the case of a drug-eluting stent (DES), the process of healing is
delayed and neointima may not form for months or even years. To prevent the formation of
platelet thrombi, dual antiplatelet therapy is given as a combination of aspirin and clopidogrel
for three months in a case of BMS and for a minimum of one year in a case of DES.
A prolonged duration of therapy is often required for a subset of patients who are highly prone to
thrombus formation. During most non-cardiac surgeries, dual antiplatelet therapy should be
continued if bleeding can be directly controlled and excessive bleeding will have no adverse
effect on the outcome of surgery. Prasugrel, another thienopyridine, is more potent and faster
acting than clopidogrel, and is therefore of great value in cases of acute coronary syndrome
during PCI, particularly in diabetics. Triple drug therapy, by adding cilastozol, is reserved for
some selected thrombotic lesions. Ticagrelor and cangrelor are two new antiplatelet agents
undergoing various clinical trials. (Cardiol J 2011; 18, 6: 712–717)
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Introduction
Percutaneous coronary intervention (PCI) using
a bare metal stent (BMS) or a drug-eluting stent
(DES) has become a widely accepted treatment for
obstructive coronary artery disease (CAD). The pro-
cedure of PCI inflicts balloon injury to the site of the
lesion, leading to activation of the coagulation cascade
which may lead to acute and subacute thrombosis
(SAT) [1]. Placement of the stent further complicates
the local coagulation process with higher chances of
thrombosis over the metal surface. Aggressive anti-
coagulation regimens have been shown to minimize
the stent thrombosis rate. However, such an approach
can also result in higher rates of vascular complica-
tions, in particular bleeding [2]. There has been am-
ple clinical research in the last decade to unravel the
optimal antiplatelet therapy, their dosage, the dura-
tion of such therapy and related issues in order to
reduce the thrombotic complications of PCI.
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Thrombotic complications of PCI
The most dreaded complications following PCI
are SAT, late stent thrombosis (LST) and very late
stent thrombosis (VLST). Thrombosis occurring
within 30 days is called SAT; thrombosis occurring
after 30 days to one year is called late stent throm-
bosis; and that occurring more than one year later
is called very LST [3, 4].The complication can re-
sult in fatal myocardial infarction (MI) in as many
as 45% of cases [5]. Vascular injury caused by high
pressure balloon dilatation and deployment of
a stent leads to adherence of activated platelets at
the site of injury. There is release of adenosine
diphosphate (ADP), tromboxane A2 and other pro-
coagulative factors. Release of these factors further
leads to platelet aggregation and the formation of
platelet-rich thrombi. The process starts almost si-
multaneously with balloon dilatation and stent
placement. Exposure of blood coagulation compo-
nents, particularly activated platelets, to the bare
metal surface of the stent makes the area vulnera-
ble to thrombosis until the stent surface gets co-
vered with a neointima [6]. In a case of BMS, the
neointima begins to form within a couple of weeks
and the chances of thrombus formation keep on
reducing until the stent is fully covered with neoin-
tima within eight to ten weeks. In a case of BMS, it
is very uncommon to encounter thrombosis beyond
this period [7–9]. DESs are very effective in reduc-
ing the chances of restenosis and thereby the need
for reintervention. They do so by reducing neoin-
timal proliferation. However, the process of stent en-
dothelialization also gets delayed by several months
or years [6]. Furthermore, sirolimus and paclitaxel
induced expression of tissue factor in the DES
stented lesion may kick off the coagulation cascade
[6]. Finally, the polymer coating on the DES can
provoke infiltration of eosinophilic cells in the ves-
sel wall suggestive of hypersensitivity reaction, and
this might contribute to a prothrombotic milieu [10].
In autopsy specimens taken from patients who
have died of LST or VLST, the stents have been
found to be inadequately covered with neointima with
thrombi over bare metal surface of the stent [10, 11].
Evolution of dual antiplatelet therapy
In previous decades, aspirin alone in small to
large doses, and subsequently in combination with
coumadin, was tried but found to be ineffective in
terms of reducing the incidence of SAT [12, 13].
A dual antiplatelet combination with ticlopidine,
a thienopyridine derivative, proved reasonably effec-
tive in reducing the incidence of SAT compared to
aspirin alone [12, 13]. However, the bone marrow
suppression associated with ticlopidine clearly re-
quired another effective agent to replace ticlopidine
in the combination. Clopidogrel was introduced in the
late 1990s. Higher efficacy and diminished likelihood
of bone marrow suppression made this new thienopy-
ridine compound very popular. Soon, clopidogrel with
aspirin became the standard care for patients under-
going PCI [14–17].
Concerns regarding clopidogrel use
Duration of use
Current guidelines of clopidogrel use in BMS
patients are clear and robust (Grade 1A evidence).
Clopidogrel 75 mg a day, along with aspirin 150 mg,
is given for a minimum of one month and ideally up
to 12 months, unless the patient is prone to bleed-
ing [18, 19]. In patients who undergo PCI for ACS,
a minimum 12 month duration is recommended
(Grade 1B evidence) [18, 19]. The recommenda-
tions for DES have varied over the last few years.
The earliest studies recommended only three
months of dual antiplatelet therapy (DAT) follow-
ing a sirolimus coated stent and six months follow-
ing a paclitaxel coated stent [20]. However, seve-
ral case reports of LST and VLST due to delayed
healing, and autopsy confirmations of inadequate
neointimal coverage for several months and years
have led to confusion regarding the period for which
DAT should be continued following DES implantation
[18, 19]. The ACC/AHA guidelines recommended
a minimum of 12 months of DAT for patients who
receive DES (Grade 1B evidence) [18, 19]. DAT for
longer than 12 months, and perhaps indefinitely, af-
ter DES is considered necessary in a subset of pa-
tients when antithrombotic benefit appears to ex-
ceed the risk for bleeding. This subset includes
patients with minimal risk of gastrointestinal or ce-
rebral bleeding and at increased risk of late stent
thrombosis (such as those with prior brachythera-
py, reduced left ventricular systolic function, com-
plex PCI, or suboptimal procedure outcome), or in
whom stent thrombosis could be catastrophic (PCI
of left main or proximal left anterior descending coro-
nary arteries). Aspirin at a dose of 75 to 162 mg/day
should be continued indefinitely in all stented pa-
tients (Grade 1A evidence) [18, 19].
Clopidogrel resistance
Depending on the definition used and the la-
boratory assay employed to measure resistance, be-
tween 4% and 68% of patients do not show adequate
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response to platelet [21–27]. Clopidogrel resistance
has been attributed to variation in gut absorption,
variation in metabolism via CYP450 enzyme, varia-
tion in the combination with its platelet P2Y12
receptor, and possibly interaction with other drugs,
especially  proton pump inhibitors (PPIs) [25]. Be-
cause of partial or complete resistance, various dose
schedules, particularly the administration of load-
ing dose, have been recommended. A 600 mg load-
ing dose of clopidogrel produces a greater maximal
antiplatelet effect, an earlier antiplatelet effect, and
reduces the likelihood of clopidogrel resistance [28–
–34]. There was no benefit found on cardiovascular
(CV) outcomes or stent thrombosis with a double
dose of clopidogrel in patients receiving DES with
high residual platelet activity on a regular clopi-
dogrel dose in the GRAVITAS trial [35]. In this tri-
al, 5,429 patients on a regular dose of clopidogrel
underwent platelet-function tests with the Verify-
Now assay (Accumetrics, San Diego, CA, USA)
12 to 24 hours after PCI; 41% of the patients from
this pool had high residual platelet reactivity (plate-
let reactivity units or PRU ≥ 230). They were ran-
domized to continue on the 75 mg regular clopi-
dogrel dosage arm or to receive another 600 mg
loading dose and a higher maintenance dose of
150 mg daily arm. Baseline characteristics of the
samples revealed that most patients were at rela-
tively low risk, with 80% having stable CAD. There
was an identical composite end-point of CV death/
/MI/stent thrombosis in both the groups (2.3%) at
six month follow-up (Table 1).
Stent thrombosis occurred in 0.5% of the high-
-dose group compared to 0.7% of the standard-dose
group but the difference was not statistically sig-
nificant. There was also no difference in bleeding
between the two groups (Table 2).
The absolute platelet reactivity was reduced
from an average of about 280 PRU at baseline to
200 PRU in the high-dose clopidogrel group, in compa-
rison to 240 PRU in the standard-dose group at 30 days.
This was a modest, albeit statistically significant,
reduction in PRU. Results at six months were virtu-
ally the same as those at three months (Table 3) [36].
TRIGGER-PCI had a similar trial design to
GRAVITAS but compared clopidogrel with prasug-
rel based on platelet-reactivity testing in stable
CAD patients post-stenting. The trial was halted
prematurely and hence could not render any note-
worthy information on whether a significant gain in
primary CV outcome could be achieved by adding
more effective antiplatelet therapy.
Finally, another trial, TRILOGY AS, compar-
ing clopidogrel and prasugrel, is still ongoing in
patients with acute coronary syndrome (ACS).
Interaction with proton pump inhibitors
Patients who are on DAT are prescribed PPI
because aspirin can be responsible for gastritis and,
in combination with clopidogrel, there are concerns
Table 1. GRAVITAS: Primary end-point.
End-point High-dose Standard-dose Hazard ratio P
clopidogrel  clopidogrel  (95% CI)
CV death/MI/stent thrombosis 2.3% 2.3% 1.01 (0.58–1.76) 0.98
CV — cardiovascular; MI — myocardial infarction
Table 3. GRAVITAS: Percentage of patients with persistently high platelet reactivity at 30 days.
Platelet reactivity units (PRU) High-dose Standard-dose P
clopidogrel  clopidogrel
≥ 230 62% 40% < 0.001
Table 2. GRAVITAS: Bleeding results.
Outcome High-dose Standard-dose P
clopidogrel  clopidogrel
GUSTO severe/moderate bleeding 1.4% 2.3% 0.10
Any GUSTO bleeding  12.0% 10.2% 0.18
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about gastrointestinal bleeding. A possible but un-
proven clinical effect of PPIs on the protection af-
forded by clopidogrel has been evaluated in a large
number of studies, with varying and often conflict-
ing conclusions [36–43]. The only large scale ran-
domized trial of omeprazole vs placebo in clopi-
dogrel users, the CONGENT trial, showed no sig-
nificant difference in CV events (HR 0.99; 95% CI
0.68–1.44) along with a significant reduction in GI
events (HR 0.34; 95% CI 0.18–0.63). However, this
trial had to be terminated early because of lack of
availability of continued funding by the sponsor. As
a result, only 3,873 of the planned sample size of
5,000 were enrolled and there were only 109 pri-
mary CV end-points [44]. In November  2009, the
US Food and Drug Administration stated that the
concomitant use of omeprazole and clopidogrel
should be avoided because of the effect on clopi-
dogrel metabolism and therefore its antiplatelet
activity [45]. Since the level of inhibition among
other PPIs varies, it is unknown to what extent oth-
er PPIs may interfere with clopidogrel. However,
esomeprazole, a PPI that is a component of ome-
prazole, inhibits CYP2C19 and should also be avoid-
ed in combination with clopidogrel. While the cur-
rent state of knowledge does not validate the state-
ment that PPIs are associated with clinical CV
events among clopidogrel users, further randomi-
zed trials are clearly needed to draw up more con-
crete evidence-based guidelines.
Dual antiplatelet therapy during
non-cardiac surgery
For elective non-cardiac surgery, DAT should
be continued for at least the minimum duration rec-
ommended for each stent type. However, in cases
where surgery is emergent, one has to evaluate the
risk of bleeding during the surgical procedure. In
most surgery where the chances of bleeding are
less, or the bleeding can be controlled directly dur-
ing surgery, it is advisable not to discontinue DAT
[46]. In some procedures, such as hip, brain or spi-
nal surgery, if needed as emergency procedures
when bleeding may be difficult to control and could
have adverse effects on the surgical outcomes, it
may be better to discontinue one of the two agents.
Thienopyridine may be discontinued for as brief
a period as possible and aspirin may be continued
uninterrupted if the 12 month period of DAT is not
finished [46].  It is recommended that for any den-
tal treatment, including extraction, or any other
major surgery including open abdominal surgery
where there is direct access to control bleeding,
DAT may be continued weighing the risk of some
extra bleed that one may encounter [46]. The con-
cept of bridging a gap in thienopyridine therapy
using an intravenous glycoprotein IIb/IIIa inhibitor
such as tirofiban is under investigation [47].
Future paradigms in antiplatelet therapy
Triple antiplatelet therapy
Triple antiplatelet therapy i.e. aspirin, clopi-
dogrel and cilostazol, compared to dual antiplatelet
therapy i.e. aspirin and clopidogrel, has shown a low-
er rate of adverse CV outcomes after stent placement
in patients with either stable or unstable coronary
disease in several studies [48–51].
This holds true for both short- and long-term
outcomes without significant difference in the rate
of bleeding. In the recent CILON-T study, a com-
bination of aspirin, clopidogrel and cilastozol in PCI
for acute MI was not associated with a significant
reduction in clinical outcomes after DES placement
compared to the standard DAT [52]. However, the
addition of cilostazol did improve post-treatment
platelet reactivity as measured by P2Y12-receptor
reaction units (PRU). Multiple studies have shown
an association between platelet activity and out-
comes. Even in the CILON-T trial, patients in the
lowest tertile of platelet reactivity (PRU values of
0 to 184 U) had zero clinical events (cardiac death,
non-fatal MI, ischemic stroke). We are yet to see if
changing therapy based on the functional platelet
knowledge changes clinical outcomes, and wheth-
er platelet reactivity is a better guide to monitor-
ing therapy among post-PCI patients.
Newer antiplatelet agents
Prasugrel is a newer drug which binds irrevers-
ibly to the P2Y12 platelet receptor, as does clopi-
dogrel. However, it has several distinct advantag-
es over clopidogrel. It has a more rapid onset of
action (an incredibly beneficial property whenever
emergency PCI is contemplated) and is able to
achieve higher degrees of platelet inhibition than
clopidogrel, while having a comparable rate of sig-
nificant bleeding [53]. Furthermore, human poly-
morphisms in gene encoding CYP450 system affect
prasugrel therapy to a lesser extent; hence, plate-
let activity is suppressed in a larger number of pa-
tients than clopidogrel.
TRITON-TIMI 38, a pivotal trial for prasugrel,
analyzed 13,608 patients with moderate to high risk
ACS undergoing PCI randomized to receive prasug-
rel with aspirin in one arm and standard DAT in the
other [54]. At an average follow-up of 14.5 months,
prasugrel was associated with a significant 2.2%
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absolute reduction and a 19% relative reduction in
death, non-fatal MI and non-fatal stroke. Diabetics
appear to derive greater benefit. The post hoc ana-
lysis revealed three subsets of patients who showed
less net clinical benefit and increased risk of bleed-
ing. These include patients with a history of stroke
or transient ischemic attack, those above 75 years,
and those weighing less than 60 kg. Based on the
TRITON-TIMI 38 results, patients in whom prasug-
rel should be considered include those with STEMI
and NSTEMI in whom a decision has been made to
withhold thienopyridine therapy until after diagnos-
tic coronary angiography. Further, it may be con-
sidered an alternative to clopidogrel in moderate or
high risk ACS undergoing PCI without the afore-
mentioned contraindications [54]. Overall, prasug-
rel appears to be an important advance in antiplate-
let therapy.
Ticagrelor and cangrelor:
Two newer antiplatelet agents
Ticagrelor differs from the thienopyridines in
that it binds reversibly, rather than irreversibly,
with the P2Y12 platelet receptor and has a more
rapid onset of action than clopidogrel [55]. It belongs
to a new chemical class of antiplatelet agents, the
cyclopentyltriazolopyrimidines. In a similar fashion
to prasugrel, treatment with ticagrelor leads to
more intense platelet inhibition than clopidogrel
[56]. In the original PLATO trial of dual antiplate-
let treatment in ACS, ticagrelor significantly re-
duced the primary outcome of vascular death, non-
-fatal MI, and non-fatal stroke compared to clopi-
dogrel (absolute risk 9.8% vs 11.7%; hazard ratio
0.84, 95% CI 0.77–0.92) [56].  Further, in a subgroup
analysis of 5,216 (28%) PLATO recruits who were
intended for non-invasive management at the time
of admission, James et al. [57] found no higher risk
of bleeding. Ticagrelor now has a class 1 recommen-
dation in the European revascularization guidelines
for use in combination with aspirin for the invasive
management of ACS [58]. A similar recommenda-
tion will perhaps soon follow for non-invasive mana-
gement [59]. Cangrelor is an intravenous non-
-thienopyridine P2Y12 receptor blocker that has not
been shown to be superior to clopidogrel in patients
with ACS undergoing PCI [37, 60].
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